AstraZeneca R&D: Aim Early To Cut Cycle Time, Build Phase II Pipeline
This article was originally published in Pharmaceutical Approvals Monthly
Current R&D strategy emphasizes improvements to R&D processes, like trying to reduce costs and cycle time. Making go/no-go decisions earlier on is also a goal, R&D execs say in an interview. The firm is in a building phase as it makes up for some major Phase III failures in recent years. AstraZeneca's current late-stage pipeline is mostly focused on lifecycle management
You may also be interested in...
In the contest to predict early winners in the pipeline game, the challenge of this decade is predictive efficacy, according to Hughes.
PhRMA's new chairman, AstraZeneca CEO David Brennan, wants to make a deal on health reform - but not necessarily the kind of tradeoff the industry made on the Medicare drug benefit
Targacept and AstraZeneca halted further development of their neuronal nicotinic receptor modulator AZD3480 for cognitive dysfunction in schizophrenia after the drug failed to meet its primary endpoint in the Phase II HALO trial, but a final decision on the compound will wait for an ongoing trial in attention-deficit/hyperactivity disorder